Leveraging 30 years of progenitor cell research and development, Elanix Biotechnologies develops and commercializes tissue regeneration products for chronic and acute wound care, as well as advanced skin care products for dermatological and gynecological applications. Founded in 2013 as a spin-out from the University Hospital of Lausanne, the company's patented progenitor cell technology utilizes fully differentiated yet immunologically neutral cells to induce tissue growth and healing. With GMP certified Master and Working cell banks, Elanix possesses vast quantities of cells. Headquartered in Nyon, Switzerland, with offices in Wiesbaden, Germany, the company is listed on the Frankfurt stock exchange under the symbol ELN.